ACER
Income statement / Annual
Last year (2022), Acer Therapeutics Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2022, Acer Therapeutics Inc.'s net income was -$26.24 M.
See Acer Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00 |
$1.26 M |
$0.00 |
$0.00 |
$432.12 K |
-$246.00 K |
$2.91 M |
$2.56 M |
$1.27 M |
$1.27 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$1.26 M
|
$0.00
|
$0.00
|
$432.12 K
|
-$246.00 K
|
$2.91 M
|
$2.56 M
|
$1.27 M
|
$1.27 M
|
| Gross Profit Ratio |
0
|
1
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$11.93 M
|
$6.51 M
|
$11.85 M
|
$13.85 M
|
$12.45 M
|
$8.73 M
|
$6.50 M
|
$10.04 M
|
$12.12 M
|
$9.18 M
|
| General & Administrative Expenses |
$12.69 M
|
$10.70 M
|
$10.96 M
|
$16.05 M
|
$9.26 M
|
$5.22 M
|
$3.12 M
|
$4.26 M
|
$3.83 M
|
$3.67 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$12.69 M
|
$10.70 M
|
$10.96 M
|
$15.05 M
|
$9.26 M
|
$5.22 M
|
$3.12 M
|
$4.26 M
|
$3.83 M
|
$3.67 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$10.63 K
|
$68.70 K
|
$2.15 K
|
$37.91 K
|
| Operating Expenses |
$24.61 M
|
$17.21 M
|
$22.80 M
|
$29.90 M
|
$21.71 M
|
$13.95 M
|
$9.86 M
|
$14.65 M
|
$16.34 M
|
$13.19 M
|
| Cost And Expenses |
$24.61 M
|
$17.21 M
|
$22.80 M
|
$29.90 M
|
$21.71 M
|
$13.95 M
|
$9.86 M
|
$14.65 M
|
$16.34 M
|
$13.19 M
|
| Interest Income |
$1.82 K
|
$0.00
|
$13.58 K
|
$471.27 K
|
$412.55 K
|
$14.85 K
|
$0.00
|
$0.00
|
$15.46 K
|
$14.99 K
|
| Interest Expense |
$101.43 K
|
$0.00
|
$0.00
|
$0.00
|
$987.00
|
$245.06 K
|
$0.00
|
$0.00
|
$1.98 K
|
$2.27 M
|
| Depreciation & Amortization |
-$198.00 K
|
-$54.76 K
|
$96.20 K
|
-$8.21 K
|
$27.74 K
|
$4.00 K
|
$238.13 K
|
$351.40 K
|
$387.78 K
|
$335.60 K
|
| EBITDA |
-$24.55 M |
-$15.88 M |
-$22.73 M |
-$28.34 M |
-$21.25 M |
-$13.95 M |
-$5.68 M |
-$2.57 M |
-$14.66 M |
-$11.53 M |
| EBITDA Ratio |
0
|
-12.6
|
0
|
0
|
-49.18
|
56.69
|
-1.95
|
-1
|
-11.53
|
-9.1
|
| Operating Income Ratio |
0
|
-12.66
|
0
|
0
|
-50.25
|
56.7
|
-2.31
|
-4.73
|
-11.85
|
-9.41
|
| Total Other Income/Expenses Net |
-$1.62 M
|
$574.40 K
|
-$82.62 K
|
-$1.02 M
|
$433.10 K
|
-$246.00 K
|
-$1.03 M
|
$67.53 K
|
$15.62 K
|
-$4.73 M
|
| Income Before Tax |
-$26.24 M
|
-$15.37 M
|
-$22.89 M
|
-$29.42 M
|
-$21.28 M
|
-$14.19 M
|
-$6.70 M
|
-$12.02 M
|
-$15.05 M
|
-$16.66 M
|
| Income Before Tax Ratio |
0
|
-12.2
|
0
|
0
|
-49.25
|
57.7
|
-2.31
|
-4.7
|
-11.83
|
-13.15
|
| Income Tax Expense |
$1.62 M
|
-$645.00 K
|
$11.81 K
|
-$538.00 K
|
$0.00
|
$0.00
|
$1.04 M
|
-$4.74 K
|
$4.13 K
|
$0.00
|
| Net Income |
-$26.24 M
|
-$15.37 M
|
-$22.90 M
|
-$29.42 M
|
-$21.28 M
|
-$14.19 M
|
-$7.98 M
|
-$12.02 M
|
-$15.05 M
|
-$16.66 M
|
| Net Income Ratio |
0
|
-12.2
|
0
|
0
|
-49.25
|
57.7
|
-2.75
|
-4.7
|
-11.83
|
-13.15
|
| EPS |
-1.77 |
-1.03 |
-2.06 |
-2.86 |
-2.49 |
-3.84 |
-11.7 |
-21.23 |
-39.67 |
-91.56 |
| EPS Diluted |
-1.77 |
-1.03 |
-2.06 |
-2.86 |
-2.49 |
-3.84 |
-11.7 |
-21.23 |
-39.67 |
-91.56 |
| Weighted Average Shares Out |
$15.77 M
|
$14.27 M
|
$11.12 M
|
$10.09 M
|
$8.56 M
|
$3.69 M
|
$680.67 K
|
$565.35 K
|
$379.63 K
|
$181.92 K
|
| Weighted Average Shares Out Diluted |
$15.77 M
|
$14.27 M
|
$11.12 M
|
$10.09 M
|
$8.56 M
|
$3.69 M
|
$680.67 K
|
$565.35 K
|
$379.63 K
|
$181.92 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
